Combination immunotherapy for advanced kidney cancer after prior treatment
Part of Cancer, Immune system & allergy, Kidney & urinary clinical trials.
This trial tests a new drug (JS004) combined with an existing immunotherapy (toripalimab) for kidney cancer that has progressed after previous immunotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have advanced or spread kidney cancer that includes clear cells, and you have already tried 1-2 immunotherapy treatments that stopped working or caused side effects.
- You are in generally good health (able to do daily activities with some help).
- You have at least one tumor that can be measured on scans.
- You are willing to provide a tumor tissue sample (from a previous biopsy or a new one).
- Your heart, liver, kidneys, and blood counts are within acceptable levels for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, toripalimab and JS004, for patients with advanced kidney cancer that has returned or spread. It aims to see if this therapy can help when other treatments have stopped working.
This trial tests a combination of two drugs — an immunotherapy (toripalimab) and a targeted therapy (axitinib) — as the first treatment for advanced kidney cancer. The approach may shrink the tumor before deciding whether and when to remove the kidney surgically.
This trial tests whether giving immunotherapy before surgery can help people with advanced kidney cancer. The goal is to see if waiting on surgery and starting with medication that boosts the immune system is safe and effective.
This trial tests a combination of targeted therapy (axitinib) and immunotherapy (toripalimab) alongside stereotactic body radiation therapy (SBRT) for kidney cancer that has come back or spread. It may be an option if you have a limited number of metastatic tumors that can be treated with radiation.
This trial tests a new drug combination given before surgery for kidney cancer that is early stage but hard to operate on. The goal is to shrink the tumor and make surgery easier.
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
Hear when a new Unresectable or Advanced Clear Cell Renal Cell Carcinoma That Has Progressed After Previous Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.